Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NEKTAR THERAPEUTICS NKTR

Healthcare
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that... see more

Recent & Breaking News (NDAQ:NKTR)

Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A

PR Newswire November 13, 2013

Nektar and Roswell Park Cancer Institute Announce Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Second-Line Treatment in Patients with Relapsed or Refractory Small Cell Lung Cancer (SCLC)

PR Newswire October 24, 2013

Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day

PR Newswire October 8, 2013

Nektar to Host Investor and Analyst R&D Day in New York City

PR Newswire October 2, 2013

Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol

PR Newswire September 30, 2013

Five Star Equities Issues New Research Reports on ACN, KIOR, NKE and NKTR

Accesswire September 27, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on BIOL, NBS, NKTR and NUS

Accesswire September 13, 2013

Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013

PR Newswire August 8, 2013

Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets

PR Newswire August 1, 2013

Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer

PR Newswire July 30, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on CNDO, NKTR, THRX and VNDA

Accesswire June 28, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on CLSN, MNKD, NKTR and VPHM

Accesswire June 24, 2013

SodaStream, Statoil, Nektar Therapeutics, Johnson & Johnson and Pfizer highlighted as Zacks Bull and Bear of the Day

PR Newswire June 21, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on DVAX, MNOV, NKTR and PLX

Accesswire June 20, 2013

Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence

PR Newswire June 19, 2013

Zacks Bull and Bear of the Day Highlights: Mueller, Cirrus Logic, Nektar Therapeutics, Novartis and Cubist Pharmaceuticals

PR Newswire June 6, 2013

Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting

PR Newswire June 3, 2013

Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting

PR Newswire June 1, 2013

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City

PR Newswire May 30, 2013

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City

PR Newswire May 16, 2013